All articles tagged with #fezolinetant
In a real-world study, fezolinetant (Veozah), a non-hormonal menopause treatment, significantly reduced hot flashes and night sweats and improved anxiety and depression symptoms within four weeks, offering a fast-acting alternative to hormone therapy for menopausal women.
England's NHS will offer Veoza (fezolinetant) as a non-hormonal treatment for menopausal hot flushes and night sweats when HRT cannot be used; NICE says it’s cost-effective and could help up to 500,000 women. Not recommended for those with breast cancer, other estrogen‑dependent cancers, or liver disease; HRT remains the first-line option. The decision applies in England; Wales and Northern Ireland often follow NICE guidance, while Scotland has not yet recommended NHS use.
Hot flashes are a common symptom of menopause that can last up to 10 years and are linked to serious health conditions. While estrogen is the first line of treatment, a newly FDA approved treatment called Veozah (fezolinetant) and an over-the-counter supplement called S-equol can also help reduce hot flashes. Many women avoid estrogen due to misinformation about its safety, but it has been shown to decrease the risk of breast cancer and all causes of mortality.
The FDA has approved a new nonhormonal medication, fezolinetant, to treat hot flashes and night sweats caused by menopause. The medication, marketed as Veozah, will be a game-changer for women who cannot or do not want to take hormone replacement therapy, such as breast cancer survivors. While not as effective as estrogen or estrogen coupled with progestin, the medication will provide relief for moderate to severe hot flashes. The medication works by targeting and blocking a receptor in the brain that regulates body temperature. A 30-day supply is expected to cost $550.
The US FDA has approved a hormone-free drug, fezolinetant, sold under the brand name Veozah, to treat moderate to severe hot flashes during menopause. The drug works by targeting the brain's temperature control center to decrease both the frequency and intensity of hot flashes in women. Prior to the FDA's approval of fezolinetant, the main treatment options for hot flashes related to menopause were hormone replacement therapy (HRT) and some types of antidepressants. Veozah is a once-a-day pill and is promising for women who cannot take hormone treatment because of other underlying health concerns.